Register today for the Congressional Briefing
From 2009-2019, the number of people with end-stage renal disease (ESRD) increased by more than 40 percent and that trajectory is predicted to continue over the next 10 years. In 2009, there were 574,000 people with kidney failure; that number increased to 809,000 in 2019. If this trend continues, there will be well over 1 million people with ESRD by 2030.
ESRD has a hugely disproportionate impact on communities of color; Black people comprise 13% of the US population but are over 35% of people on dialysis. We also know that COVID-19 has had a devastating impact on people with ESRD – mortality and hospitalization rates for these patients much higher than the general population. Further, ESRD not only disrupts lives, but it also has a high cost to society in terms of medical costs, lost wages and mortality.
This briefing will examine WHY we are in this situation and WHAT we can do about it.
This session is made possible thanks to the generous support of the American Kidney Fund's 2022 Corporate Members.
President and Chief Executive Officer
Chief Medical Officer at the CMS Innovation Center, Centers for Medicare and Medicaid Services at HHS
Vice President of Patient Services and Education
AKF Ambassador and Founder & CEHD of iAdvocate